Health Care/Hospital

Harbour BioMed Announces IND Approval for Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Feb. 21, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that China National Medical Products Administration (NMPA) had approved its investigational new drug (IND) application for HBM9378 (or SKB378 as referred to ...

2022-02-21 20:29 2135

Biosion, Inc. Appoints Joel Edwards, MBA, as Chief Business Officer

NEWARK, Del. and NANJING, China, Feb. 21, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment ofJoel Edwards as chief business officer. In this position, he is responsible for strategic leadership over all aspects of the c...

2022-02-21 13:00 1651

Meihua International Medical Technologies Co., Ltd. Announces Closing of $39.4 Million Initial Public Offering

YANGZHOU, China, Feb. 18, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today announced the closing of...

2022-02-19 05:30 6242

OliPass Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002

SEOUL, South Korea, Feb. 18, 2022 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced that the dosing of pain killer OLP-1002 commenced for a Phase 2a trial in osteoarthritis patients with pain. The Phase 2a study was appr...

2022-02-18 23:00 3102

Keymed Bio Joins Hang Seng Family of Indexes

HONG KONG, Feb. 18, 2022 /PRNewswire/ --  According to the quarterly review results of Hang Seng Family of Indexes, Keymed Biosciences Inc. (2162. HK) was included a constituent stock of: * Hang Seng Composite Index; * Hang Seng Small Cap (Investable) Index; * Hang Seng Stock Connect Hong K...

2022-02-18 22:10 6445

TransThera Announces that the IND Application of TT-01488, a Non-covalent Reversible BTK Inhibitor, for the Treatment of B-Cell Lymphomas has been Approved by the FDA in the US and Officially Accepted by the NMPA in China

NANJING, China, Feb. 18, 2022 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. ("TransThera") announced that the U.S. Food and Drug Administration ("FDA") approved the Investigational New Drug("IND") application of TT-01488, a non-covalent reversible Bruton's Tyrosine Kinase ("BTK") inhibitor,...

2022-02-18 22:00 4086

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on ...

2022-02-18 08:19 1698

Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma

SUZHOU, China and PALO ALTO, Calif., Feb. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today...

2022-02-17 21:30 2517

Flat Medical joins the Stay Connected(R), the International Organization for Safer Neuraxial Anesthesia

TAIPEI, Feb. 17, 2022 /PRNewswire/ -- Flat Medical Co., Ltd., a MedTech company specializing in safety solutions for anesthesia and critical care procedures, has announced that it has just joined the Stay Connected®, a joint communication initiative on behalf of the industry to advocate and educa...

2022-02-17 21:00 1570

Meihua International Medical Technologies Co., Ltd. Announces Pricing of $36,000,000 Initial Public Offering

YANGZHOU, China, Feb. 16, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today announced the pricing of...

2022-02-16 20:34 3990

PharmaBlock Appoints Dr. Zhengtian Gu as Senior Vice President of Quality and Regulatory Affairs

NANJING, China, Feb. 16, 2022 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr. Zhengtian (Titan) Gu as Senior Vice President of Quality and Regulatory A...

2022-02-16 20:00 1560

Travecta Therapeutics Appoints Leading Experts to Expand its Scientific Advisory Leadership Team

PRINCETON, N.J. and SINGAPORE, Feb. 15, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced significant expansion of the Scientific Advisory B...

2022-02-15 21:00 1558

HPG: New Breakthrough in Virus Inactivation with Green Tea Catechin (EGCg)

TOKYO, Feb. 15, 2022 /PRNewswire/ -- HPG Co., Ltd. (Chuo-ku, Tokyo) has successfully developed a water-soluble formulation technology of highly concentrated catechin EGCg (Epigallocatechin gallate) with excellent storage stability and initiated procedures for a patent application for the technolo...

2022-02-15 16:00 1406

AffaMed Therapeutics Announces IND Clearance by US FDA for AM712 - a Novel Bispecific Biologic for the Treatment of Retinal Vascular Diseases

SHANGHAI, Feb. 15, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, today announced that the United States Food and Drug Administration (FD...

2022-02-15 15:05 1362

Largest Hospital in Queensland, Australia Acquires Multiple Accuray Radixact® Systems with the ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies

- Royal Brisbane and Women's Hospital acquisition is intended to expand access to potentially life-saving radiotherapy treatments to more patients - Hospital was the first in Australia to invest in the TomoTherapy® helical radiotherapy delivery platform and is now the first to secure the latest ...

2022-02-15 05:10 4103

U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent

NANJING, China and SHANGHAI and SAN JOSE, Calif., Feb. 13, 2022 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innov...

2022-02-14 08:25 2519

Visionflex Chooses Vonage to Power its Next-Generation Remote Healthcare and Diagnostic Services

HOLMDEL, N.J., Feb. 14, 2022 /PRNewswire/ -- Vonage (Nasdaq: VG), a global leader in cloud communications helping businesses accelerate their digital transformation, has been chosen byVisionflex to power the future of telehealth and remote diagnostic equipment for medical professionals through th...

2022-02-14 06:32 2551

Qilian International Holding Group Limited Reports Fiscal Year 2021 Financial Results

JIUQUAN, China, Feb. 11, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), aChina-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the fiscal year ...

2022-02-12 06:05 6227

Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients

SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the enrollment and dosing of first patient inChina in its multi-regi...

2022-02-11 20:40 4165

WuXi STA Wins 2022 CMO Leadership Awards in All Six Core Categories

SHANGHAI, Feb. 10, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced that it received 2022 CMO Leadership Awards in all six core categories including Capabilities, Compatibility, Expertise, Quality, Reliability and Service and scored as a 2022 CMO Leadership Award Champi...

2022-02-11 10:00 1794
1 ... 172173174175176177178 ... 278